文献速递肝病消化道肿瘤与早癌

伴有持续病毒学应答的丙型肝炎肝硬化患者肝细胞癌风险:治疗方案的作用

The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen.
PubMed 文献 · J Hepatol · 2017-11-16

基于苏格兰HCV临床数据库1997-2016年数据,纳入857例接受抗病毒治疗并获得持续病毒学应答的肝硬化初治患者,31.7%接受无干扰素方案。无干扰素治疗在单变量分析中与肝细胞癌风险显著升高相关(HR 2.48,p=0.021),但多变量调整基线因素后无显著风险(aHR 1.15,p=0.744)。结论提示肝细胞癌发生率升高与基线风险因素/患者选择相关,而非无干扰素方案本身。

要点

  • 857例肝硬化患者中31.7%接受无干扰素方案,随访期间46例发生肝细胞癌。
  • 单变量分析无干扰素治疗与肝细胞癌风险显著升高相关(HR 2.48,p=0.021)。
  • 多变量调整后无干扰素治疗无显著风险(aHR 1.15,p=0.744)。

核心结论

  • 持续病毒学应答后无干扰素治疗者肝细胞癌发生率较高与基线风险因素/患者选择相关,而非无干扰素方案本身。

研究设计与样本

  • 利用苏格兰HCV临床数据库,识别1997-2016年接受抗病毒治疗并获得持续病毒学应答的肝硬化初治患者,随访至死亡、肝细胞癌发生或2017年1月31日最早日期,采用Cox回归比较治疗方案(无干扰素 vs 含干扰素)的肝细胞癌风险。

主要发现

  • 共857例患者符合标准,31.7%接受无干扰素方案;随访期间46例发生肝细胞癌。
  • 单变量分析中无干扰素治疗与肝细胞癌风险显著升高相关(HR 2.48,p=0.021)。
  • 多变量调整基线因素后无干扰素治疗无显著风险(aHR 1.15,p=0.744)。
  • 接受无干扰素治疗者更可能为:年龄较大、白种人、Child-Turcotte-Pugh B/C vs Child-Turcotte-Pugh A、血小板减少、非基因3型、有治疗经验。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Previous studies have reported a high frequency of hepatocellular carcinoma (HCC) occurrence in patients with advanced liver disease, after receipt of interferon (IFN)-free therapy for hepatitis C virus (HCV) infection. Our objective was to verify and account for this phenomenon using data from the Scottish HCV clinical database. METHODS: We identified HCC-naïve individuals with liver cirrhosis receiving a course of antiviral therapy in Scotland from 1997-2016 resulting in a sustained virologic response. Patients were followed-up from their treatment start date to the earliest of: date of death, date of HCC occurrence, or 31 January 2017. We used Cox regression to compare the risk of HCC occurrence according to treatment regimen after adjusting for relevant co-factors (including: demographic factors; baseline liver disease stage; comorbidities/health behaviours, virology, and previous treatment experience). HCC occurrence was ascertained through both the HCV clinical database and medical chart review. For our main analysis, treatment regimen was defined as IFN-free vs. IFN-containing. RESULTS: A total of 857 patients met the study criteria, of whom 31.7% received an IFN-free regimen. Individuals receiving IFN-free therapy were more likely to be: older; of white ethnicity, Child-Turcotte-Pugh B/C vs. Child-Turcotte-Pugh A; thrombocytopenic; non-genotype 3; and treatment experienced. HCC occurrence was observed in 46 individuals during follow-up. In univariate analysis, IFN-free therapy was associated with a significantly increased risk of HCC (HR: 2.48; p = 0.021). However, after multivariate adjustment for baseline factors, no significant risk attributable to IFN-free therapy persisted (aHR: 1.15, p = 0.744). CONCLUSION: These findings suggest that the higher incidence of HCC following sustained virologic response with IFN-free therapy relates to baseline risk factors/patient selection, and not the use of IFN-free therapy per se. LAY SUMMARY: We examined the risk of liver cancer in 857 patients with cirrhosis in Scotland who received hepatitis C antiviral therapy and achieved a cure. We compared the risk of first-time liver cancer in patients treated with the newest interferon-free regimens, to patients treated with interferon. After accounting for the different characteristics of these two treatment groups, we found no evidence that interferon-free therapy is associated with a higher risk of liver cancer.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Innes H, Barclay ST, Hayes PC, et al. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen. J Hepatol. 2017. PMID: 29155019. doi:10.1016/j.jhep.2017.10.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。